01—Abstract
Summary
Summary of the 10-Q filed November 12, 2024. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. reported strong revenue growth in the third quarter of 2024, with total revenues reaching $7.5 billiona, a 7% increase year-over-year, driven primarily by robust performance in its HIV segment.
This growth was partially offset by significant non-cash charges, including an $1.8 billionb impairment related to the Trodelvy NSCLC IPR&D asset and higher acquired IPR&D expenses, which resulted in a net loss of $1.3 billion for the nine-month period. Despite the net loss, the company demonstrated positive operating cash flow, highlighting the underlying strength of its commercial operations and the ongoing demand for its key products. The company continues to strategically invest in its pipeline and expand its portfolio through acquisitions and collaborations.
Notable developments include the FDA's accelerated approval of Livdelzi for primary biliary cholangitis and positive Phase 3 data for lenacapavir in HIV prevention, positioning Gilead for future growth. However, the company faces ongoing legal challenges and potential patent expirations, which remain key areas for investor attention.
02—Key points
Key Highlights
- Total revenues increased 7% to $7.5 billion for the three months ended September 30, 2024, and 6% to $21.2 billion for the nine months ended September 30, 2024.
- HIV product sales showed significant strength, increasing by 9% to $5.1 billion for the third quarter and 5% to $14.2 billion year-to-date.
- A substantial $1.8 billion in-process research and development (IPR&D) impairment charge was recorded in the third quarter related to the Trodelvy NSCLC asset, and a total of $4.2 billion for the nine-month period.
- The company completed the acquisition of CymaBay Therapeutics for $3.9 billion net cash consideration, adding seladelpar to its liver disease portfolio.
- FDA granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis.
- Net cash provided by operating activities for the nine months ended September 30, 2024, was $7.9 billion.
- The company announced plans to voluntarily withdraw the U.S. accelerated approval of Trodelvy for a specific urothelial cancer indication.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Gilead Sciences, Inc. kept $0.17.
- Revenue$7.54B100.0%
- Cost of revenue−$1.57B20.9%
- Gross profit$5.97B79.1%
- Operating costs−$5.08B67.4%
- Operating income$888.0M11.8%
- Interest, other & tax$365.0M4.8%
- Net income$1.25B16.6%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 12, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $7.54B$7.05B | +7.0% |
| Cost of Revenue | $1.57B$1.56B | +0.6% |
| Gross Profit | $5.97B$5.49B | +8.8% |
| SG&A Expenses | $1.43B$1.31B | +9.0% |
| Operating Expenses | $6.66B$4.43B | +50.3% |
| Operating Income | $888.00M$2.62B | −66.1% |
| Net Income | $1.25B$2.18B | −42.5% |
| EPS (Basic) | $1.00$1.75 | −42.9% |
| EPS (Diluted) | $1.00$1.73 | −42.2% |
| Shares Outstanding (Basic) | 1.25B1.25B | −0.1% |
| Shares Outstanding (Diluted) | 1.25B1.26B | −0.2% |
05—Questions
Frequently Asked Questions
What drove the significant impairment charge in the third quarter?
The company recorded an $1.8 billion impairment charge in the third quarter (and a total of $4.2 billion year-to-date) related to its in-process research and development (IPR&D) intangible asset for Trodelvy in non-small cell lung cancer (NSCLC). This was triggered by disappointing results from the Phase 3 EVOKE-01 study and a subsequent strategic decision to discontinue development for the second-line indication in metastatic NSCLC.
How did the CymaBay acquisition impact the financial results?
Gilead completed the acquisition of CymaBay Therapeutics for $3.9 billion net cash in March 2024. This transaction added seladelpar to Gilead's liver disease portfolio and resulted in significant acquired IPR&D expenses of $3.9 billion recognized during the first quarter of 2024. While this impacted short-term profitability, it strengthens Gilead's pipeline in liver disease.
What is the outlook for Gilead's HIV business?
Gilead's HIV business continues to show strong performance, with product sales increasing by 9% in the third quarter and 5% year-to-date. Key products like Biktarvy and Descovy are driving this growth through increased demand and higher average realized prices. The company also presented positive Phase 3 data for lenacapavir in HIV prevention, which is expected to lead to future regulatory filings.
What are the key legal risks facing Gilead?
Gilead faces several significant legal risks, including ongoing litigation concerning PrEP patents, patent infringement lawsuits with generic manufacturers challenging the exclusivity of key products like Biktarvy and Symtuza, and antitrust and consumer protection lawsuits related to HIV drugs. Additionally, product liability lawsuits concerning kidney, bone, and tooth injuries allegedly caused by certain HIV medications remain a concern. The company is also subject to government investigations related to its sales and marketing practices.
06—Continue